loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for BMF-219

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    BMF-219

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
    Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

    06 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/06/2895065/0/en/Biomea-Fusion-Announces-BMF-219-in-Diabetes-Placed-on-Clinical-Hold.html

    GLOBENEWSWIRE
    06 Jun 2024
    Share Share
    Biomea Fusion Completes Enrollment 3 Arms BMF-219 Type 2 Diabetes Trial
    Biomea Fusion Completes Enrollment 3 Arms BMF-219 Type 2 Diabetes Trial

    30 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/30/2890844/0/en/Biomea-Fusion-Announces-Completion-of-Enrollment-of-First-3-Arms-in-Phase-2-Expansion-Cohorts-of-COVALENT-111-Study-for-BMF-219-in-Type-2-Diabetes.html

    GLOBENEWSWIRE
    30 May 2024
    Share Share